Kazia receives a $2 million development milestone after Sovargen doses the first patient in a Phase 1b/2a paxalisib trial for rare seizure disorders. The event also leaves Kazia eligible for up to $17 million in further development and regulatory milestones, plus sublicensing Revenue and royalties on net sales.

Key Highlights

  • The Phase 1b/2a study evaluates paxalisib in epilepsy associated with FCD T2 and TSC.
  • Kazia and Sovargen entered their exclusive licensing agreement in March 2024.
  • The Sovargen trial reached its first-patient milestone.
  • The study is evaluating paxalisib in adults with FCD T2, TSC and hemimegalencephaly.

Sovargen Trial Reaches First-Patient Milestone

KAZIA Therapeutics Limited (NASDAQ: KZIA) is a biotechnology company. The study is assessing paxalisib in patients with intractable epilepsy linked to FCD T2 and TSC. The agreement covers all countries worldwide except mainland China, Hong Kong, Macao and Taiwan. Kazia and Sovargen entered the licensing arrangement in March 2024. FCD T2 and TSC are described as rare, genetically driven neurological disorders involving overactivation of the mTOR pathway and treatment-resistant seizures.

Further Milestones Remain Available

Kazia is eligible for up to $17 million in further development and regulatory milestone payments under the agreement. The arrangement also provides for a percentage of sublicensing revenue and royalties on net sales of products containing paxalisib. The companies said the clinical study will generate data as the program progresses. The release also identifies the trial as a Phase 1b/2a evaluation in adults with FCD T2, TSC and hemimegalencephaly.